Back to top
more

NovoCure Limited (NVCR)

(Delayed Data from NSDQ)

$18.08 USD

18.08
1,272,314

+0.18 (1.01%)

Updated Aug 19, 2024 04:00 PM ET

After-Market: $18.10 +0.02 (0.11%) 7:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

NovoCure (NVCR) Reports Q3 Loss, Lags Revenue Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of 16.67% and 2.85%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Medpace (MEDP) Beats Q3 Earnings and Revenue Estimates

Medpace (MEDP) delivered earnings and revenue surprises of 39.46% and 8.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of -64.29% and 4.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in NovoCure (NVCR): Can Its 8% Jump Turn into More Strength?

NovoCure (NVCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of 76.47% and 1.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

NovoCure (NVCR) Reports Q4 Loss, Lags Revenue Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of -150% and 1.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate NovoCure (NVCR) to Report a Decline in Earnings: What to Look Out for

NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Charles River Laboratories (CRL) Tops Q4 Earnings and Revenue Estimates

Charles River (CRL) delivered earnings and revenue surprises of 2.89% and 1.52%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Avantor, Inc. (AVTR) Q4 Earnings and Revenues Top Estimates

Avantor, Inc. (AVTR) delivered earnings and revenue surprises of 9.09% and 0.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

NovoCure (NVCR) Reports Q3 Loss, Misses Revenue Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of -116.67% and -6.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate NovoCure (NVCR) to Report a Decline in Earnings: What to Look Out for

NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Accuray (ARAY), C-RAD Ink Deal to Enhance Breast Cancer Treatment

Accuray's (ARAY) latest agreement is likely to improve breast cancer treatment.

NovoCure (NVCR) Reports Q2 Loss, Misses Revenue Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of -800.00% and -5.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

NovoCure (NVCR) Q2 Earnings Preview: What's in the Cards?

NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Debanjana Dey headshot

Oncology Space Gains Momentum in 2021: 5 Stocks to Focus on

Oncology stocks like OncoCyte (OCX), PerkinElmer (PKI), Catalent (CTLT), Cardiff Oncology (CRDF) and NovoCure (NVCR) are expected to continue their run over the next few months.

Zacks.com featured highlights include: Manchester United, NovoCure, Palantir Technologies and JD.com

Zacks.com featured highlights include: Manchester United, NovoCure, Palantir Technologies and JD.com

Rimmi Singhi headshot

4 Toxic Stocks That May Disrupt Your Peace & Portfolio

Investors who can pinpoint the overhyped toxic stocks and discard them at the right time are the ones who are poised to benefit.

Why NovoCure (NVCR) Might Surprise This Earnings Season

NovoCure (NVCR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

NovoCure (NVCR) is Overbought: Is A Drop Coming?

NovoCure Limited (NVCR) has moved higher as of late, but there could definitely be trouble on the horizon for this company.

Analysts Estimate NovoCure (NVCR) to Report a Decline in Earnings: What to Look Out for

NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Company News for Apr 14, 2021

Companies in the news are: MFNC, NVCR, RIGL, VTVT

NovoCure (NVCR) Moves 49.6% Higher: Will This Strength Last?

NovoCure (NVCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

NovoCure (NVCR) Q4 Earnings and Revenues Miss Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of -69.23% and -0.01%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?